Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2021
Price :
$35
*
At a glance
- Drugs Avanafil (Primary)
- Indications Erectile dysfunction
- Focus Registrational; Therapeutic Use
- Acronyms REVIVE; REVIVE-G
- 26 Jun 2013 Avanafil approved for treatment of erectile dysfunction in the EU based on results of the RIVIVE, REVIVE-Diabetes and REVIVE-RP, according to a VIVUS media release.
- 28 Apr 2012 Results from this trial were used to support US FDA approval of avanafil for the treatment of erectile dysfunction.
- 17 Jan 2012 Results published in the Journal of Sexual Medicine and a VIVUS media release.